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ABSTRACT
Small interfering RNA (siRNA)-based therapies are
proving to be efficient for treating liver-associated
disorders. However, extra-hepatic delivery remains
challenging, limiting therapeutic siRNA utility. We
synthesized a panel of fifteen lipid-conjugated siR-
NAs and systematically evaluated the impact of con-
jugate on siRNA tissue distribution and efficacy. Gen-
erally, conjugate hydrophobicity defines the degree
of clearance and the liver-to-kidney distribution pro-
file. In addition to primary clearance tissues, sev-
eral conjugates achieve significant siRNA accumu-
lation in muscle, lung, heart, adrenal glands and fat.
Oligonucleotide distribution to extra-hepatic tissues
with some conjugates was significantly higher than
with cholesterol, a well studied conjugate, suggest-
ing that altering conjugate structure can enhance
extra-hepatic delivery. These conjugated siRNAs en-
able functional gene silencing in lung, muscle, fat,
heart and adrenal gland. Required levels for pro-
ductive silencing vary (5–200 g/g) per tissue, sug-
gesting that the chemical nature of conjugates im-
pacts tissue-dependent cellular/intracellular traffick-
ing mechanisms. The collection of conjugated siRNA
described here enables functional gene modulation
in vivo in several extra-hepatic tissues opening these
tissues for gene expression modulation. A systemic
evaluation of a panel of conjugated siRNA, as re-
ported here, has not previously been investigated
and shows that chemical engineering of lipid siRNAs
is essential to advance the RNA therapeutic field.
INTRODUCTION
Therapeutic oligonucleotides––i.e. antisense oligonu-
cleotides (ASOs), small interfering RNA (siRNA) and
aptamers––are emerging as a new class of drugs in addition
to small molecules and biologics (1). Their advantages over
conventional drugs include: (i) ease of design––rationally
achieved based on sequence information and straightfor-
ward screening, leading to drug candidates within short
periods of time; (ii) ability to target disease genes previously
considered ‘undruggable’; and (iii) unprecedented potency
and duration of effect (2,3). Clinical success is dependent
on their efficient delivery to disease tissues.
Conjugate-mediated delivery is emerging as the clinically
dominant delivery paradigm for siRNAs. This mode of de-
livery requires full chemical stabilization of siRNAs (4–
6) because unmodified siRNAs are rapidly degraded and
cleared from the circulation by kidney filtration, leading
to minimal bioavailability in tissues (7). Chemical scaffolds
that replace every 2′ hydroxyl (8–10), modify terminal nu-
cleotide linkages (11,12) and stabilize the 5′ phosphate (13–
16) maximize the in vivo activity of siRNAs.
For liver delivery, the trivalent N-acetylgalactosamine
(GalNAc) conjugate binds with high specificity and affin-
ity to the asialoglycoprotein receptor on hepatocytes, re-
sulting in specific oligonucleotide delivery to and robust
gene silencing in hepatocytes (17–20). This delivery strat-
egy has revolutionized the development of oligonucleotide
therapeutics to treat liver diseases, with more than a dozen
clinical programs (21). The success of the GalNAc platform
demonstrates that functional tissue delivery of therapeutic
oligonucleotides is a foundation for any clinical exploration.
Another class of conjugates widely used for improving
siRNA delivery is lipids (22). The majority of studied lipid-
conjugated siRNAs, such as cholesterol-conjugated siR-
NAs, accumulate in the liver (∼60–80%) (7,23,24). How-
ever, cholesterol-modified siRNAs also exhibit accumula-
tion and productive silencing in kidney (25), muscle (26)
and placenta (27). Moreover, local injection of cholesterol-
modified siRNA leads to functional gene silencing in brain,
vagina and skin (28–31). The impact of other lipid conju-
gates on extra-hepatic siRNA delivery has never been eval-
uated.
Here we systematically evaluate how different lipid con-
jugates impact siRNA tissue distribution and silencing ac-
tivity in vivo. We synthesized a panel of siRNAs conju-
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gated to 15 different lipid moieties, including saturated and
non-saturated fatty acids, steroids and vitamins, with or
without a phosphocholine polar head group. In general,
the degree of siRNA hydrophobicity correlates with accu-
mulation in kidneys (less hydrophobic) or liver (more hy-
drophobic). Though most of the injected siRNAs accumu-
late in clearance organs, we identified conjugates that enable
functional siRNA delivery to heart, lung, fat, muscle and
adrenal gland. In these tissues, accumulation levels were 3-
to 10-fold higher than cholesterol-conjugated siRNAs. The
siRNA tissue concentrations required for productive silenc-
ing varied depending on the tissue and conjugate, with no
perfect correlation between compound accumulation and
efficacy being observed. Our findings provide proof of prin-
ciple that lipid engineering is a viable path for improving
extra-hepatic delivery and target silencing.
MATERIALS AND METHODS
Synthesis of lipid functionalized solid support for the prepa-
ration of conjugated siRNAs
Lipid moieties (except -tocopheryl succinate) were
directly attached via a peptide bond to a controlled
pore glass (CPG) functionalized by a C7 linker, as
described (32). To synthesize phosphocholine deriva-
tives, amino C7 CPG was first functionalized with
phosphocholine (33). Briefly, Fmoc-L-serine tert-butyl
(TCI America) was phosphitylated using 2′-cyanoethyl-
N,N-diisopropylchlorophosphoramidite (ChemGenes).
The resulting phosphoramidite was coupled to choline
p-toluenesulfonate (Alfa Aesar) using 5-(ethylthio)-1H-
tetrazole (ETT) as an activator. The phosphine ester was
then oxidized, and the carboxylic acid and phosphate
ester groups were deprotected (i.e. tert-butyl and cya-
noethyl groups removed). The resulting intermediate was
attached to the amino C7 CPG via a peptide bond to form
phosphocholine-functionalized CPG. The Fmoc group was
removed, and the selected lipid moiety was attached via
a peptide bond to the CPG. All lipid-functionalized solid
supports were obtained with a loading of 55 mol/g.
Synthesis of -tocopheryl succinate-conjugated siRNAs
-tocopheryl succinate was attached to the amino group at
the 3′ ends of siRNA sense strands after synthesis, deprotec-
tion, and purification of sense strands synthesized on amino
C7CPGor phosphocholine-functionalized aminoC7CPG.
N-hydroxysuccinimide -tocopheryl succinate and purified
sense strands were combined in a solution of 0.1 M sodium
bicarbonate, 20% (v/v) dimethylformamide and incubated
overnight at room temperature. One-tenth volume 3 M
sodium acetate (pH 5.2) was added to obtain a final concen-
tration of 0.3 M sodium acetate. Three volumes 95% (v/v)
ethanol were added, and the mixture was vortexed and then
placed for 1h at −80◦C. The solution was pelleted by cen-
trifugation for 30 min at 5200 × g. The pellet containing
the lipid-conjugated siRNA sense strand was dissolved in
water, purified and desalted as described below.
Oligonucleotide synthesis
An Expedite ABI DNA/RNA synthesizer was used
to synthesize oligonucleotides following standard pro-
tocols. Sense strands were synthesized at 10 mole
scales on lipid-functionalized CPG or amino C7 CPG
(for the post-synthetic conjugation of -tocopheryl
succinate moiety) supports. Antisense strands were syn-
thesized at 10 mole scales on CPG functionalized
with Unylinker® (ChemGenes, Wilmington, MA). 2′-
O-methyl phosphoramidites (ChemGenes, Wilmington,
MA, USA), 2′-fluoro phosphoramidites (BioAutomation,
Irving, TX, USA), Cy3-labeled phosphoramidites (Gene
Pharma, Shanghai, China) and custom synthesized (E)-
vinylphosphonate phosphoramidites (33) were prepared
as 0.15 M solutions in dry acetonitrile. Trityl groups
were removed using 3% dichloroacetic acid (DCA) in
dichloromethane for 80 s, phosphoramidites were cou-
pled using 0.25 M 5-(benzylthio)-1H-tetrazole (BTT)
in acetonitrile as an activator for 250 s and uncoupled
monomers were capped with 16% N-methylimidazole
in tetrahydrofuran (CAP A) and 80:10:10 (v/v/v)
tetrahydrofuran:acetic anhydride:2,6-lutidine (CAP B)
for 15 s. Sulfurizations were carried out with 0.1 M
solution of 3-[(dimethylaminomethylene)amino]-3H-1,2,4-
dithiazole-5-thione (DDTT) in acetonitrile for 3 min.
Oxidation was performed in 0.02 M iodine in tetrahydro-
furan:pyridine:water (70:20:10, v/v/v) for 80 s.
Deprotection and purification of oligonucleotides
Sense strands were cleaved and deprotected using 1 ml of
40% aq. methylamine at 45◦C for 1 h. Antisense strands
were first deprotected with a solution of bromotrimethyl-
silane:pyridine (3:2, v/v) in dichloromethane (5 ml) for
the (E)-vinylphosphonate deprotection and then cleaved
and deprotected with 10 ml of 40% aq. methylamine at
45◦C for 1 h. Sense and antisense oligonucleotide solutions
were frozen in liquid nitrogen for a few minutes and dried
overnight in a Speedvac under vacuum. The resulting pel-
lets were suspended in water and purified using an Agilent
Prostar System (Agilent, Santa Clara, CA, USA). Sense
strands were purified over a Hamilton HxSil C18 column
(150 × 21.2) in a continuous gradient of sodium acetate:
90% Buffer A1 (50 mM sodium acetate in 5% acetonitrile),
10% Buffer B1 (acetonitrile) to 10% Buffer A1, 90% Buffer
B1 at a flow rate of 5 ml/min for 18 min at 70◦C. Antisense
strands were purified over aDionexNucleoPac PA-100 (9×
250) in a continuous gradient of sodium percholate: 100%
BufferA2 (30%acetonitrile inwater) to 20%BufferA2, 80%
Buffer B2 (1 M sodium perchlorate, 30% acetonitrile) at a
flow rate of 10 ml/min for 30 min at 65◦C. Purified oligonu-
cleotides were collected, desalted by size-exclusion chro-
matography using a Sephadex G25 column (GEHealthcare
Life Sciences, Marlborough, MA, USA) and lyophilized.
Analysis of oligonucleotides
Oligonucleotide purity and identity was determined by Liq-
uid Chromatography-Mass Spectrometry (LC-MS) analy-
sis on an Agilent 6530 accurate-mass Q-TOF LC/MS (Ag-
ilent technologies, Santa Clara, CA, USA). Liquid chro-
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matography was performed using a 2.1 × 50-mm Advance-
Bio oligonucleotide column (Agilent technologies, Santa
Clara, CA) and a gradient of buffers A (9 mM trimethy-
lamine, 100 mM hexafluoroisopropanol in water) and B
(9 mM triethylamine/100 mM hexafluoroisopropanol in
methanol). Sense strand gradient: 1% B to 40% B from 0
to 2 min, 40% B to 100% B from 2 to 10.5 min. Antisense
strand gradient: 1% B to 12% B from 0 to 2 min, 12% B
to 30% B from 2 to 10.5 min and 30% B to 100% B from
10.5 to 11min. Relative hydrophobicities of conjugated siR-
NAs were determine by measuring the retention time on an
Agilent Prostar System equipped with a Water HxSil C18
column (75 × 4.6) in a gradient of 100% buffer A (0.1 M
trimethylamine acetate in water) to 100% buffer B (0.1 M
trimethylamine acetate in acetonitrile) at a flow rate of 1
ml/min for 15 min at 60◦C.
Injection of conjugated siRNAs into mice
Animal experiments were performed in accordance with an-
imal care ethics approval and guidelines of University of
Massachusetts Medical School Institutional Animal Care
and Use Committee (IACUC, protocol number A-2411).
Female FB/NJ mice (The Jackson Laboratory) 7- to 8-
weeks old were injected subcutaneously with phosphate
buffered saline (PBS controls) orwith 20mg/kg siRNA (un-
conjugated or lipid-conjugated) suspended in phosphate-
buffered saline (PBS) (160 l). For distribution studies,
three mice per conjugate were injected (n = 49, including
controls). For the efficacy studies, eight mice per conjugate,
per gene were studied (n= 272, including controls). For the
toxicity studies, three mice per conjugate were injected (n=
30, including controls).
Fluorescence microscopy
At 48 h post-injection, mice were euthanized and perfused
with PBS. Tissues were collected and immersed in 10% for-
malin solution overnight at 4◦C. Tissues were embedded in
paraffin and sliced into 4-m sections that were mounted
on glass slides. Tissue sections on glass slides were deparaf-
finized by incubating twice in xylene for 8 min. Sections
were rehydrated in an ethanol series from 100% to 95% to
80%, for 4 min each. Slides were then washed twice with
PBS, 2 min each, incubated with DAPI (250 ng/ml, Molec-
ular Probes) in PBS for 1 min and washed again in PBS
for 2 min. Slides were mounted with PermaFluor mounting
medium (Molecular Probes) coverslips, and dried overnight
at 4◦C. Sections were imaged at 5 × and 40 × using a Leica
DM5500B microscope fitted with a DFC365 FX fluores-
cence camera.
Peptide nucleic acid (PNA) hybridization assay
Tissue concentrations of antisense strands were determined
using a peptide nucleic acid (PNA) hybridization assay
(34,35). Tissues (15mg) were placed inQIAGENCollection
Microtubes holding 3-mm tungsten beads and lysed in 300
l MasterPure tissue lysis solution (EpiCentre) containing
0.2 mg/ml proteinase K (Invitrogen) using a QIAGEN Tis-
sueLyser II. Lysates were then centrifuged at 1000 × g for
10 min and incubated for 1 h at 55◦ to 60◦C. Sodium dode-
cyl sulphate (SDS) was precipitated from lysates by adding
20 l 3 M potassium chloride and pelleted centrifugation at
5000 × g for 15 min. Conjugated siRNAs in cleared super-
natant were hybridized to a Cy3-labeled PNA probe fully
complementary to the antisense strand (PNABio, Thou-
sand Oaks, CA, USA). Samples were analyzed by HPLC
(Agilent, Santa Clara, CA, USA) over a DNAPac PA100
anion-exchange column (Thermo Fisher Scientific), in a
gradient of sodium perchlorate, as follows: Buffer A: 50%
water; 50% acetonitrile; 25 mM Tris–HCl, pH 8.5; 1 mM
ethylenediaminetetraacetate. Buffer B: 800mMsodiumper-
chlorate in buffer A. Gradient conditions: 10% buffer B
within 4 min, 50% buffer B for 1 min and 50% to 100%
buffer B within 5 min. Cy3 fluorescence was monitored and
peaks integrated. Final concentrations were ascertained us-
ing calibration curves generated by spiking known quanti-
ties of lipid-conjugated siRNA into tissue lysates from an
untreated animal. Spiked samples for calibration and ex-
perimental samples were processed and analyzed under the
same laboratory conditions.
In vivo mRNA silencing experiments
At 1-week post-injection, mice were euthanized and per-
fused with PBS. Tissues were collected and stored in
RNAlater (Sigma) at 4◦C overnight. mRNAwas quantified
using the QuantiGene 2.0 Assay (Affymetrix). The 1.5-mm
punches (three punches per tissue) were placed in QIAGEN
Collection Microtubes holding 3-mm tungsten beads and
lysed in 300 l Homogenizing Buffer (Affymetrix) contain-
ing 0.2 mg/ml proteinase K (Invitrogen) using a QIAGEN
TissueLyser II. Samples were then centrifuged at 1000 × g
for 10 min and incubated for 1 h at 55◦ to 60◦C. Lysates and
diluted probe sets (mouse Htt, mouse Ppib or mouse Hprt)
were added to the bDNA capture plate and signal was am-
plified and detected as described by Coles et al. (36). Lu-
minescence was detected on a Tecan M1000 (Tecan, Mor-
risville, NC, USA).
Statistical analysis
Data were analyzed using GraphPad Prism 7.01 software
(GraphPad Software, Inc., San Diego, CA, USA). For each
independent efficacy experiment in mice, the level of si-
lencing was normalized to the mean of the control (PBS)
group. Data were analyzed using non-parametric one-way
ANOVA with Bonferroni’s test for multiple comparisons,
with significance calculated relative to both PBS controls
and non-targeting controls (Ntc).
RESULTS
Synthesis of conjugated siRNAs library
To evaluate how lipid conjugates affect siRNA distribution
in vivo, we synthesized a panel of siRNAs conjugated with
naturally-occurring lipids, including: the unsaturated fatty
acids docosahexaenoic acid (DHA, 22:6 n-3) and eicos-
apentaenoic acid (EPA, 20:5 n-3); the saturated fatty acid
docosanoic acid (DCA, 22:0); the sterols cholesterol (Chol)
and lithocholic acid (LA); and the vitamins retinoic acid
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Figure 1. Library of studied lipid conjugated siRNAs. The desired conjugate is attached to the 3′ end of the sense strand of the siRNA though a C7 linker
(left column) or a C7 linker functionalized with a phosphocholine group (PC) (right column).
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(RA) and -tocopheryl succinate (TS) (Figure 1). A signif-
icant fraction of circulating fatty acids are esterified with
phosphatidylcholine or other head groups (37,38). There-
fore, we synthesized each lipid conjugate with or without
phosphocholine (PC) (33) to test whether this polar head
group affects the distribution of lipid-conjugated siRNAs
in vivo. As controls, we synthesized unconjugated siRNAs
(Unconj.) and siRNAs with the PC head group only (no
lipid). Each lipid conjugate was covalently attached to the
3′ end of the siRNA sense strand, which tolerates a range
of covalent modifications (7,39,40). The siRNAs were fully
chemically modified for maximal stability and minimal in-
nate immune activation (see ‘Materials and Methods’ sec-
tion).
The chemical compositions of lipids had a profound ef-
fect on the hydrophobicity of conjugated siRNAs, as de-
termined by retention time in reversed-phase High Per-
formance Liquid Chromatography (HPLC) (41). Lipid-
conjugated siRNA retention times ranged from 1 to 12.2
min (Supplementary Figure S1). In general, compounds
with a PC head group eluted 0.5 to 1.3 min earlier than their
counterparts without a PC head group, suggesting that PC
reduces hydrophobicity. Oligonucleotides without a lipid
eluted the fastest, with PC-siRNA (1 min) eluting 4.7 min
earlier than unconjugated siRNA (5.7 min).
To our knowledge, our panel of lipid-conjugated siRNAs
is the largest collection to be synthesized, purified and char-
acterized to date.
Experimental design to evaluate the impact of lipid moiety on
siRNA tissue accumulation and efficacy
Conjugated siRNA in vitro efficacy has minimal predictive
value for in vivo distribution. To evaluate how the lipid moi-
ety affects conjugated siRNA tissue distribution and effi-
cacy, we designed an experiment (Figure 2) that uses three
different assays. The experimental plan was performed for
the 15 conjugated and one unconjugated siRNA, with each
being injected subcutaneously intomice (n= 321 total mice,
including controls) at a 20 mg/kg dose (Day 0).
For distribution studies, three mice per conjugated
siRNA (n = 49 mice, with controls) were sacrificed at Day
2 post injection and 15 tissues per mouse––liver, kidney,
adrenal gland, lung, heart, thymus, spleen, pancreas, intes-
tine, fallopian tube, bladder, fat, muscle, injection site and
skin––were collected (735 total samples). To evaluate the
impact of lipid conjugates on spatial and cell-type specific
siRNA distribution, we used fluorescence microscopy to vi-
sualize siRNA sense strands, which were labeled at the 5′-
end with a Cy3 fluorophore. To quantify tissue antisense
strand accumulation, we used a PNA hybridization assay
(34,35). The PNA hybridization assay is not dependent on
the presence of Cy3 on the sense strand; it directly quanti-
fies the functionally-active non-labeled antisense strand and
informs on the relative distribution of different compounds
in different tissues. Thus, we could simultaneously evaluate
spatial tissue distribution and quantify the antisense strands
in the same samples. The PNA hybridization assay enables
detection of a positive signal on a negative background,
thus three mice per conjugate was sufficient to define tissue
accumulation. We used overall tissue accumulation (all 15
tissues, adjusted by organ weight) to estimate injected-dose
body retention versus initial kidney filtration.
The third assay used the remaining mice injected at Day 0
to examine the correlation between siRNA tissue accumu-
lation and silencing. For this silencing efficacy study, eight
mice per conjugated siRNA (n = 272 mice, with Ntc) were
sacrificed atDay 7 post injection. Lipid-conjugated siRNAs
targeted two different genes: Huntingtin (Htt) (31) or Cy-
clophilin B (Ppib) (42). We chose these targets because both
(i) have validated siRNA sequences available, (ii) are widely
expressed in the body, and (iii) are expressed at different lev-
els (Htt low, and Ppib high). Per lipid conjugate, eight mice
were injected with siRNAHtt and eight were injected with
siRNAPpib to detect signal reduction in the context of a pos-
itive background. Studies were powered to detect 15–20%
modulation with 80% confidence. After sacrifice and tissue
collection, wemeasuredPpib,Htt, andHprt (hypoxanthine-
guanine phosphoribosyl transferase, a housekeeping gene)
mRNA levels using the Quantigene Assay.
Cy3 dye has no major impact on tissue distribution profile of
lipid-conjugated siRNA
The Cy3 fluorophore is slightly hydrophobic, and it has
been previously stipulated that its presence may impact sin-
gle stranded non-conjugated ASO delivery. In this study, we
found that the relative contribution of Cy3 label to lipid-
conjugated siRNA hydrophobicity was minimal. Indeed,
while DCA or PC-DCA conjugation to the siRNA sense
strand shifts reverse-phase HPLC retention times by 5 or
8 min compared to unconjugated sense strands, the rela-
tive impact of adding Cy3 dye is <0.5 min (Supplementary
Figure S2). To evaluate if this slight change in hydropho-
bicity would affect siRNA tissue distribution profiles, we
synthesized DCA and PC-DCA conjugated siRNAs with
and without Cy3 label, injected them subcutaneously into
mice (n= 3 per group), and evaluated tissue antisense strand
accumulation (PNA hybridization assay, Figure 3). We ob-
served no significant difference in primary and secondary
tissue accumulations, indicating that the Cy3 label has no
major impact on lipid-conjugated siRNA tissue distribu-
tion. Next, we evaluated the efficacy of Cy3 and non-Cy3
conjugated siRNAs (n = 6 per group) in nine tissues (liver,
kidneys, skin, lung, heart, adrenal glands, fat, spleen and
muscle, Supplementary Figure S3). We observed statisti-
cally significant silencing in all tissues except kidney, with
no significant difference in the degree of silencing, except
in the heart––Cy3 conjugated compounds were active (45%
and 30% silencing, P < 0.0001) whereas non-Cy3 conju-
gated siRNAs were not.
These findings suggest that Cy3 has no impact on
siRNA tissue distribution profile. However, minor changes
in siRNA hydrophobicity due to Cy3 may impact produc-
tive silencing in a tissue-specific manner. This should be
considered when interpreting the reported data.
The chemical nature of the lipid conjugate defines the
liver/kidney distribution profile
Oligonucleotides preferentially distribute to two tissues:
liver and kidney. For ASOs, size and phosphorothioate
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Figure 2. Experimental plan describing the study of one conjugated siRNA inmice. The experiment was performed for 15 conjugated and one unconjugated
siRNA. In total, 321mice were injected (included PBS-injected controls). For distribution studies, threemice per lipid-conjugated siRNAHtt were sacrificed.
Fifteen tissues per mouse (liver, kidneys, lung, heart, thymus, spleen, pancreas, adrenal glands, intestine, fallopian tube, bladder, fat, muscle, skin at injection
site and skin away from injection site) were collected and analyzed by fluorescencemicroscopy andHigh Performance Liquid Chromatography for antisense
strand quantification using a PNA hybridization assay. For efficacy studies, eight mice injected with conjugated siRNAHtt and eight mice injected with
conjugated siRNAPpibper lipid conjugate were sacrificed. The expression ofHttmRNA or PpibmRNA in tissues were measured using QuantiGene Assay.
Figure 3. The presence of fluorophore Cy3 on the lipid-conjugated siRNA does not significantly affect siRNA distribution in vivo. Tissue accumulation
levels of (A) Cy3-labeled and unlabeled DCA-conjugated siRNA (B) or Cy3-labeled and unlabeled PC-DCA conjugated siRNA were similar in 15 tissues.
siRNA quantification was performed by PNA hybridization assay (average of three mice per conjugate ± SD) after a single subcutaneous injection of 20
mg/kg conjugated siRNA and tissue collection after 48 h.
(PS) modifications define the relative liver/kidney distribu-
tion via serum protein binding mechanisms. Large fully-PS
ASOs preferentially distribute to liver due to tight serum
protein binding. Decreasing ASO size/PS content reduces
serum binding affinity, shifting accumulation to kidney
proximal epithelia, which retain the non serum-binding
ASO fraction during clearance (11,43,44).
For conjugated siRNAs, the chemical nature of the lipid
conjugate, rather than size and PS content, had a pro-
found impact on the relative liver-to-kidney distribution.
Figure 4 shows representative fluorescent images (Figure
4A) and antisense strand quantification (Figure 4B) of liver
and kidney. Unconjugated siRNAs distributemostly to kid-
neys; our siRNA configuration contains a 13-PS backbone
(within 35 nt) that supports retention during filtration. Con-
jugated siRNAs exhibited enhanced kidney and liver ac-
cumulation compared to unconjugated siRNA. The high-
est kidney levels (57 pmol of antisense strand/mg of tis-
sue) were achieved by LA-siRNAs (three times higher than
unconjugated siRNA). Cholesterol-siRNAs exhibited the
highest liver accumulation (36 pmol of antisense strand/mg
of tissue). Generally, compounds with higher kidney accu-
mulation had lower liver accumulation, and vice versa. Like
ASOs, this trend is defined by serum binding profile: com-
pounds with higher delivery to kidney preferentially bind
to high-density lipoproteins (HDL), and compounds with
high liver delivery bind to low-density proteins (LDL) (Os-
born et al., NAR, in this issue) (22).
There is no direct correlation between degree of hy-
drophobicity and liver accumulation. The most hydropho-
bic compound (TS-siRNA, Supplementary Figure S1)
showed equal liver and kidney accumulation, indicating
that other factors contribute to the observed profile. Over-
all, these data demonstrate that lipid conjugation can be
used to alter the liver-to-kidney distribution profile, and en-
hance kidney delivery.
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Figure 4. The conjugate defines the ratio of liver to kidney distribution. (A) Representative fluorescence images of kidney and liver sections from mice
injected subcutaneously with 20 mg/kg Cy3-labeled lipid-conjugated siRNAs. Nuclei stained with DAPI. Three mice per conjugate were injected and
tissue collected 48 h after injection. Images taken at 5 × magnification and collected at the same laser intensity and acquisition time. Scale, 1 mm. (B)
siRNA quantification in kidney (cortex) and liver was performed by PNA hybridization assay (average of three mice per conjugate ± SD).
The chemical nature of the conjugates affects cell-type distri-
bution in kidney and liver
In the kidney, all conjugates preferentially delivered to kid-
ney proximal epithelia, consistent with its role in filtration.
Figure 5A shows representative examples of siRNA deliv-
ery to the medulla and glomerulus, an easily distinguish-
able histological structure responsible for large protein re-
absorption and involved in many human diseases. The de-
gree of distribution to glomerulus and medulla varied sig-
nificantly among conjugated-siRNAs, and could not be ex-
plained by overall organ accumulation or compound hy-
drophobicity. LA-siRNAs achieved the highest accumula-
tion in the kidney but were not distributed beyond epithelial
cells. Unconjugated siRNAs, which differ in hydrophobic-
ity from LA-siRNA, showed a similar distribution pattern:
no accumulation in the glomerulus or medulla. By contrast,
EPA- (andDHA-) siRNAs, which have relatively similar hy-
drophobicity to LA-siRNAs, showed very clear delivery to
the glomerulus, with diffuse staining and distinct foci be-
ing detected. Interestingly, PC-EPA and PC-DHA siRNAs
did not accumulate in the glomerulus. Moreover, PC-RA
siRNAs showed significant accumulation in the medulla,
whereasRA-siRNAs exhibited lowdistribution. These find-
ings suggest that individual conjugate properties, including
the PC moiety, impact distribution within the kidney.
A similar phenomenon was observed in the liver (Fig-
ure 5B). Three conjugated siRNAs (cholesterol, PC-TS and
DCA siRNAs) with similar overall delivery to the liver ex-
hibited distinct distributions within the organ. Cholesterol-
siRNAs were detected in Kupffer cells (liver residual
macrophages) and hepatocytes. PC-TS siRNAs had a sim-
ilar distribution pattern, but with lower accumulation in
hepatocytes and some detectable endothelial retention. The
majority of DCA siRNAs accumulated in endothelial cells
andKupffer cells, with significantly reduced hepatocyte dis-
tribution. Since these compounds have similar hydropho-
bicity (Supplementary Figure S1) and serum binding pro-
files (Osborn et al., NAR, in this issue) (22), the difference in
delivery within the liver is likely due to individual conjugate
properties. For unconjugated siRNA, which had minimal
liver delivery, distribution was almost exclusively limited to
Kupffer cells.
The chemical nature of the lipid conjugate has a profound im-
pact on the degree of overall siRNA retention
We measured antisense strand accumulation in fifteen tis-
sues that comprise most of the mouse body, allowing us to
estimate the fraction of injected siRNA dose retained after
48 h (Figure 6). The relative mass of each tissue has been ex-
perimentally defined, or approximated based on published
mouse organ weights (45–47).
More than 85%of unconjugated siRNAwas cleared from
the body within minutes after injection, and the majority
of the retained siRNA accumulated in kidney proximal ep-
ithelial cells. The addition of a lipid conjugate improved
siRNA overall body retention; highly hydrophobic conju-
gates like DCA and cholesterol allowed quantitative siRNA
tissue distribution, indicating relatively low contribution of
kidney filtration to serum clearance.
Generally, more hydrophobic compounds (PC-TS, DCA
and cholesterol siRNAs) were retained to a higher extent
than less hydrophobic compounds (PC, PC-LA and PC-
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Figure 5. The conjugate impacts the cell-type distribution in kidney and liver. Representative fluorescence images of (A) kidney cortex and kidney medulla
or (B) liver sections from mice injected subcutaneously with 20 mg/kg Cy3-labeled lipid-conjugated siRNAs. Nuclei stained with DAPI. Three mice per
conjugate were injected and tissue collected 48 h after injection. Images taken at 40×magnification and collected at the same laser intensity and acquisition
time. Scale, 50 m.
Figure 6. The nature of the lipid conjugate has a profound impact on siRNA tissue retention. Bar graph showing percent of the injected dose cumulatively
retained in mice across all 15 tissues 48 h after a single subcutaneous injection of 20 mg/kg conjugated siRNA (average of n = 3 mice). Stacked bars
indicate the percent of the retained dose in liver, kidney, site of injection and others tissues. More than 80% of unconjugated siRNAs are cleared while
highly hydrophobic compounds are retained quantitatively.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/47/3/1082/5245439 by U
niversity of M
assachusetts M
edical School user on 05 June 2019
1090 Nucleic Acids Research, 2019, Vol. 47, No. 3
Figure 7. Conjugated siRNAs accumulate into extra-hepatic tissues, accumulation defines by the structure of the conjugate. Bar graph showing the quantity
of the antisense strand of conjugated siRNAs present in heart, lung, muscle and fat 48 h after a single subcutaneous injection with 20 mg/kg (n = 3 mice
per conjugate ± SD). siRNA quantification was measured by PNA hybridization assay. DCA and PC-DCA conjugates improve extra-hepatic siRNA
accumulation compared to cholesterol.
EPA siRNAs), with some exceptions. For example, the pres-
ence of the PC group, which generally descreases hydropho-
bicity, had a variable impact on retention: PC-DHA, PC-TS
and PC-RA siRNAs showed higher retention (∼20%) than
their non-PC head group counterparts. This indicates that
hydrophobicity is not the single determinant for overall tis-
sue retention.
Consistent with this notion, compounds with signifi-
cantly different hydrophobicity profiles (PC-DHA and TS
siRNAs, Supplementary Figure S1) showed similar (∼65%)
body retention. Thus, the nature of the conjugate has an im-
pact on siRNA retention on top of overall serum binding-
defined clearance (Osborn et al., NAR, in this issue) (22).
DCA and PC-DCA conjugates improve extra-hepatic deliv-
ery of siRNA compared to cholesterol
To date, cholesterol is the only conjugate that has been ex-
plored for extra-hepatic delivery of siRNAs. To evaluate the
impact of different conjugates on siRNA extra-hepatic de-
livery, we analyzed the distribution of lipid-conjugated siR-
NAs 48 h after injection in adrenal glands, lung, heart, thy-
mus, spleen, pancreas, intestine, fallopian tube, bladder, fat,
muscle and skin (at and far from the injection site). Supple-
mentary Figures S4–18 show fluorescence microscopy im-
ages (5 × and 40 × magnification) of each tissue for each
lipid-siRNA, and antisense strand concentration in each tis-
sue. The quantitative data for all 16 compounds in all 15
tissues are summarized in Supplementary Figure S19.
Figure 7 shows quantification of antisense strand accu-
mulation in heart, lung, muscle and fat. It is immediately
clear that DCA and PC-DCA siRNAs distributed to extra-
hepatic tissues significantly more than the others. In lung,
EPA-siRNAs also showed significant accumulation. Fig-
ure 8 shows relative enhancement of tissue antisense strand
accumulation of DCA-conjugated compounds compared
to cholesterol-conjugated compounds. DCA accumulation
was nine-fold higher in lung, and 3-fold higher in heart,
fat and muscle compared to cholesterol. This finding sug-
gests that modulating lipid conjugate configuration can al-
ter compound tissue distribution, and potentially enhance
extra-hepatic delivery.
Lipid-conjugated siRNAs enable functional gene silencing in
several extra-hepatic tissues, including heart, lung, muscle,
fat and adrenal glands
To determine if lipid-conjugated siRNAs accumulate to lev-
els sufficient for productive silencing, we injected mice with
lipid-conjugated siRNAs targeting Htt (31) or Ppib (42). A
week later, we measured Ppib, Htt and Hprt mRNA levels.
At the dose tested (20 mg/kg), all conjugated siRNAs were
well tolerated: we observed no adverse events or changes in
blood chemistry (Supplementary Figure S37). For tissues
that retained, for themajority of the compounds, more than
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Figure 8. Relative improvement of DCA conjugated siRNA extra-hepatic tissue accumulation compared to cholesterol conjugated siRNA. Bar graph
showing the ratio between the quantity of the DCA-siRNA antisense strands and cholesterol-siRNA antisense strands present in 15 tissues 48 h after a
single subcutaneous injection with 20 mg/kg (n = 3 mice per conjugate ± SD). siRNA quantification was measured by PNA hybridization assay. DCA
accumulation was 3- to 4-fold higher in heart, muscle and fat, ∼6-fold higher in skin (systemic) and 9-fold higher in lung.
5 ng of conjugated siRNA per mg of tissue (liver, kidney,
skin injection site, spleen, adrenal glands, heart, lung and
skin), we measured the activity of all 15 conjugated siR-
NAs and the unconjugated siRNA. For the remaining or-
gans (intestine, bladder, fat, muscle, pancreas, thymus and
fallopian tube), we measured the activity of the conjugated
siRNA with the highest accumulation level for each tissue.
The silencing efficiency of each compound in each tissue is
shown in Supplementary Figures S20–34, and data are sum-
marized in a heat map in Supplementary Figure S35. Ntc
showed no significant reduction in target gene expression,
indicating that the observed silencing is due to sequence-
specific effects, not the general chemical scaffold. Uncon-
jugated siRNA induced silencing only in the kidney, con-
firming that statistically significant silencing depends on
conjugate-mediated delivery. In general, the ability of a con-
jugated siRNA to silence in a tissue was similar for both
targets.
Figure 9 shows representative data for delivery and func-
tional silencing in key tissues for the best-delivered conju-
gated siRNA per tissue: DCA siRNA for heart, PC-DCA
siRNA for muscle, fat, and adrenal gland, and EPA siRNA
for lung. These compounds induce 31–55% silencing and
all observed effects were statistically significant (P < 0.001,
One-way ANOVA with Bonferroni correction) relative to
PBS and Ntc. The exact degree of silencing differed slightly
between the two tested targets, likely due to variable cell-
type specific expression and degree of nuclear mRNA re-
tention.
These data demonstrate the feasibility of functional
extra-hepatic delivery of siRNAs, and identify particular
conjugates that enable the highest reported siRNA accu-
mulation in extra-hepatic tissues to date. Further sequence
optimization combined with repetitive dosing will be neces-
sary to achieve full silencing.
We observed that higher oligonucleotide tissue accumula-
tion tended to translate into silencing at high degrees of ac-
cumulation (Supplementary Figure S36). However, this re-
lationship was not absolute, indicating that oligonucleotide
tissue accumulation levels do not directly predict function-
ality. Figure 10 shows examples of several conjugated siR-
NAs that accumulate in tissues to the same extent but
produce functionally different results. Unconjugated, PC-
conjugated, and EPA-conjugated siRNAs showed similar
liver accumulation, but EPA-siRNAs induced∼50% silenc-
ing while PC and unconjugated siRNAs were not func-
tional. The same phenomena can be observed in kidneys,
adrenal glands and heart. This was specifically striking for
kidneys, where many compounds accumulate significantly
(>300 ng/mg), yet do not demonstrate functional silencing.
For example, PC-LA siRNAs (536 ng/mg; Supplementary
Figure S5) did not support silencing, while PC-EPA siR-
NAs, which accumulate in kidney to the same degree, in-
duced 30% silencing (Supplementary Figure S21). This sug-
gests that the chemical nature of the lipid conjugate influ-
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Figure 9. Accumulation of conjugated siRNA in several extra-hepatic tissues such as heart, muscle, fat, adrenal glands and lung are sufficient to induce
mRNA silencing. Representative fluorescence images of heart, muscle, fat, adrenal glands and lung sections from mice injected subcutaneously with 20
mg/kg Cy3-labeled lipid-conjugated siRNAs or PBS. Nuclei stained with DAPI. Three mice per conjugate were injected and tissue collected after 48 h.
Images taken at 40×magnification and collected at the same laser intensity and acquisition time. Scale, 50m. For the measurement ofHuntingtin (Htt) or
Cyclophilin B (Ppib) mRNA levels, mice were injected subcutaneously with 20 mg/kg of conjugated siRNA (n = 16 per conjugate: 8 with siRNA targeting
Htt and 8 with siRNA targeting Ppib, as well as non-targeting controls). The tissues were collected after 1 week and mRNA levels were measured using
QuantiGene® (Affymetrix), normalized to a housekeeping gene, Hprt (Hypoxanthine-guanine phosphoribosyl transferase) and presented as percent of
PBS control (mean ± SD).
ences internalization mechanisms and/or degree of endoso-
mal escape, which profoundly affects functional silencing.
DISCUSSION
GalNAc-conjugated siRNAs have dominated the recent de-
velopment of therapeutic oligonucleotides for liver indica-
tions. TheGalNAcmoiety drives specific delivery to and ac-
tivity in hepatocytes (17–19). Here we show that lipid conju-
gates support much broader delivery of siRNAs and enable
functional silencing in many tissues, including liver, kid-
ney, lung, heart, muscle, spleen, fat and adrenal glands. To
date, only one hydrophobic conjugate––cholesterol––has
been explored for extra-hepatic delivery, with demonstrated
functional silencing in placenta (27) and muscle (26). Our
study found that some lipid conjugates, particularly DCA
and PC-DCA, support higher siRNA accumulation than
cholesterol in extra-hepatic tissues, including muscle, heart,
fat and lung, without causing overt toxicity. This suggests
that lipid conjugate engineering can enhance extra-hepatic
delivery, and expand the therapeutic potential of siRNAs
beyond the liver.
To broaden delivery of siRNA to tissues, they must be re-
tained in the body. Yet, the majority of unconjugated siR-
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Figure 10. The efficiency of target mRNA silencing does not necessarily correlate with siRNA accumulation level. Graphs showing target mRNA silencing
(relative to PBS) for different conjugates with similar tissue accumulation (right Y-axis, bar). Mice were injected subcutaneously with 20 mg/kg lipid-
conjugated siRNAs (n = 3 ± SD, 48 h for antisense strand quantification; n = 8 ± SD, 1 week for target gene silencing QuantiGene). While several
conjugates show similar tissue accumulation, the functional silencing is conjugate-specific.
NAs are expected to be cleared on first passage through
the kidney because their size, ∼13 kDa, is within the limit
of active filtration (∼40 kDa). Indeed, ∼85% of unconju-
gated siRNA was rapidly cleared from the body. The re-
tained unconjugated siRNA mainly accumulated in kidney
proximal epithelia. This retention is due to the PS modi-
fications in our siRNA design (13 PS bonds within a 35-nt
scaffold), and is similar to the retention mechanism of short
single-stranded PS-ASOs (11,43,44). Lipid conjugates sig-
nificantly increased overall siRNA tissue retention, with a
trend for highly hydrophobic siRNAs (cholesterol, DCA,
PC-TS conjugated) being retained to a higher degree than
less hydrophobic siRNAs (EPA- and DHA-conjugated),
but this relationship was not absolute.
The observed increase in overall tissue retention is likely
due to reduced clearance rates (34), which increase tissue
exposure. Similar to small molecules, lipid conjugates dif-
ferentially bind to serum proteins, which affects siRNA dis-
tribution (liver-to-kidney distribution ratio) (23) (Osborn
et al., NAR in this issue) (22). However, serum binding
is not the only factor defining distribution. Both choles-
terol and DCA-siRNA preferentially interact with serum
LDL (Osborn et al., NAR, in this issue) (22). Yet their dis-
tribution in vivo was very different. DCA-siRNA showed
higher accumulation in extra-hepatic tissues, such as fat,
lung, muscle and heart compared to cholesterol-siRNA.
Moreover, while their overall liver delivery was similar,
cholesterol-siRNA accumulated in hepatocytes and Kupf-
fer cells and DCA siRNA showed a clear preference for en-
dothelial cells. Thus, serumbinding profilemay define organ
exposure, but the nature of the conjugate impacts spatial
intra-organ distribution and relative rates of internalization
by different cell types.
Similarly, in the kidney, only EPA- and DHA-siRNA
delivered to the glomerulus. However, functionalization
of EPA- and DHA-siRNA with a PC head group elim-
inated this accumulation. The PC moiety also impacted
medulla distribution: PC-RA, but not RA, enabled signif-
icant siRNA medulla delivery. These data support the no-
tion that chemical engineering of lipid-conjugated siRNA
can be used to alter intra-organ distribution. Future stud-
ies should evaluate whether cell-specific kidney delivery is
functionally active. This will require the development of
compounds targeting genes expressed exclusively in one cell
type.
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The imperfect correlation between siRNA tissue accu-
mulation and productive silencing was most pronounced in
the kidney, where many conjugated siRNAs accumulated
significantly (>30 g/g) but were not efficacious. The na-
ture of the conjugate may define productive silencing by im-
pacting cellular internalization and/or endosomal escape.
In general, relatively high siRNA accumulation was neces-
sary to produce efficacy in the kidney, indicating that the
primarymechanism of kidney retention is tubular filtration.
When retention occurs as a byproduct of filtration, the ma-
jority of internalized siRNA is trapped non-productively.
By contrast, cellular internalization in muscle and fat re-
sults from active endocytosis, and relatively low accumula-
tion (4–7 g/g) is sufficient for productive silencing. This
observation is consistent with a recent report that found re-
quired siRNAmuscle accumulation levels for productive si-
lencing are much lower than that for liver (Vasant Jadhav,
OTS meeting, 2017).
Similar to the years of chemical evolution that have
substantially improved the efficacy and safety of another
siRNA delivery approach: lipid-based nanoparticles (LNP)
(48,49), we expect that further lipid engineering will en-
hance conjugated siRNA extra-hepatic efficacy and deliv-
ery. One advantage of direct siRNA conjugation over LNP
is the elimination of the ‘particle size’ effect, which largely
defines initial LNP clearance (50). Indeed, differences in
fenestrated capillary between tissues lead to the extravasa-
tion of particles with different diameters: ∼2 nm in heart,
muscle, lung, and skin;∼30 nm in kidneys; and∼150 nm in
liver and spleen. Thus, advancements in chemical engineer-
ing of lipid-conjugated siRNAs will open up a wider array
of tissues for therapeutic intervention.
The potential for widespread siRNA delivery also comes
with limitations. Lipid-conjugated siRNAs are not deliv-
ered to specific tissues, and most of the injected dose will be
delivered to primary clearance tissues, including liver, kid-
ney and spleen. Nevertheless, lipid-siRNAs could be used
to silence: (i) targets that are exclusively expressed in the
disease tissue, or (ii) targets that are widely expressed, but
loss of activity is tolerated in healthy tissues. For example,
fully chemically stabilized cholesterol-conjugated siRNAs
have been used to silence soluble FTL1, which is overex-
pressed in placentas of pregnant subjects with preeclamp-
sia (27). Though cholesterol-siRNA targeting sFLT1 is effi-
ciently delivered to placenta (∼8% of injected dose), it also
accumulates in the liver and kidney, where sFLT1 silencing
is believed to be tolerated and irrelevant for disease progres-
sion.DUX4 inmuscular dystrophy is a similar type of target
(51). The use of lipid conjugates offers potential gene mod-
ulation in many tissues, as long as target and clinical indica-
tion are carefully considered and matched to the pharma-
cologic and safety profile of the lipid-siRNA conjugate.
This study reports the first example of chemically engi-
neered lipid-conjugated siRNAs for systemic delivery and
shows that medicinal chemistry efforts to better improve
extra-hepatic tissue accumulation and efficacy is essential
to advance the RNA therapeutic field. Future expansion of
the chemical space of lipid moieties will establish a path to-
ward enhancing siRNA delivery and potency.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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